Recursion Strategy and Business Model

Executive Overview

Recursion is a Salt Lake City-based clinical-stage TechBio company founded in 2013. Its core strategy is to industrialize drug discovery by combining automated experimental biology, high-content imaging, machine learning, and computational chemistry inside what it calls the Recursion OS. Unlike a traditional biotech built around one or two molecules, Recursion operates as both a platform company and a therapeutics developer: it advances its own pipeline in rare disease and oncology while also running discovery collaborations with large pharmaceutical companies, including Bayer and Roche/Genentech. As of the first quarter of 2024, Recursion remained pre-commercial and reported $13.8 million of quarterly revenue, derived primarily from collaboration agreements rather than product sales. Recent moves such as the 2023 acquisitions of Cyclica and Valence Discovery, and the launch of the NVIDIA-powered BioHive-1 supercomputer in late 2023, show that management is trying to deepen chemistry and AI capabilities rather than simply add more pipeline assets. Operationally, Recursion is centered in the U.S. with additional technology and chemistry capabilities in Canada, while its partnership and clinical footprint extends internationally.

Recursion at a Glance

Logo
Common name	Recursion
Full legal name	Recursion Pharmaceuticals, Inc.
Headquarters	Salt Lake City, Utah, United States
Ownership	Public company
Ticker	RXRX
Exchange	NASDAQ
Market Cap	$1.67B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2013; Nasdaq IPO in 2021; acquisitions of Cyclica and Valence Discovery in 2023; NVIDIA strategic investment and BioHive-1 launch in 2023
Industry or industries	Biotechnology, drug discovery, artificial intelligence-enabled life sciences, TechBio
Key products or services	AI-enabled drug discovery platform, internal therapeutic pipeline, partnered discovery collaborations, computational chemistry capabilities
Geographic footprint	U.S.-centered operations with additional technology and chemistry capabilities in Canada; partnerships and clinical activities that extend into Europe and other markets
Business segments as officially reported	One operating and reportable segment
Company website	https://www.recursion.com/

1. What Is the Strategy of Recursion?

Recursion’s public materials describe a company trying to change how medicines are discovered, not just which medicines it develops. The best way to understand that strategy is through the Playing to Win framework.

1. 1a. What is the winning aspiration of Recursion?

   Recursion’s stated mission is to decode biology to radically improve lives. In practical strategic terms, its aspiration is to make drug discovery more programmable, data-driven, and scalable than in traditional biotech. Winning for Recursion does not appear to mean becoming a conventional single-asset biotech; it means building a repeatable discovery engine that can produce more viable targets and compounds, advance an internal pipeline, and attract high-value collaborations with major pharmaceutical companies. As of early 2024, the company had not framed success around a long-range revenue or margin target in the way a mature industrial company might. Instead, the public emphasis was on platform scale, portfolio productivity, clinical validation, and external validation from partners.

2. 1b. Where does Recursion play?

   Recursion plays at the intersection of biotechnology and advanced computing. Therapeutically, it has concentrated much of its internal pipeline on areas such as rare disease and oncology, where smaller, genetically or biologically defined populations may offer clearer signals and faster proof of concept. Commercially, it also plays in partnered discovery, selling access to its platform and scientific capabilities to large pharmaceutical companies. Geographically, the business is centered in North America, but its partner set and potential end markets are global. The important boundary choice is that Recursion is not trying to serve every life-sciences workflow; it is focused on discovery and early development where large-scale data, automation, and machine learning may materially improve decision quality.

3. 1c. How does Recursion plan to win?

   Recursion is trying to win through differentiation, not cost leadership. Its thesis is that proprietary experimental data, generated at scale in automated labs and linked to chemistry and machine learning, can produce a better discovery process than either traditional wet-lab biotech or pure software-first AI drug discovery. The company’s approach is distinctive because it integrates data generation, model building, computational chemistry, and therapeutic development inside one system. Its partnership model also matters: alliances can validate the platform, generate non-dilutive revenue, and expand the range of biology Recursion can explore without funding every program itself.

4. 1d. What capabilities must Recursion have in place?

   To make that strategy work, Recursion needs unusual capabilities across several domains at once: automated experimental biology, high-content imaging, data engineering, machine learning, computational chemistry, medicinal chemistry, translational biology, and clinical development. It also needs alliance-management capability because a meaningful share of its current revenue comes from collaborations. The 2023 acquisitions of Cyclica and Valence Discovery suggest that management believed advanced chemistry and AI capabilities were strategic gaps worth filling through acquisition.

5. 1e. What management systems does Recursion require?

   Recursion needs management systems that connect platform economics to pipeline decisions. That means portfolio governance that can compare internal programs with partnered opportunities, milestone-based resource allocation, and feedback loops that capture learning from every experiment and clinical readout. It also requires strong data governance, quality systems, and alliance-management processes. Because the company is still pre-commercial, a critical management system is capital allocation discipline: deciding how much to invest in platform scale, how many internal assets to push forward, and when to use partnerships or external capital to preserve runway.

2. What Are the Current Strategic Initiatives of Recursion?

• Advance priority clinical programs to produce real-world proof points. As of early 2024, Recursion’s disclosed clinical-stage priorities included REC-994 for cerebral cavernous malformation, REC-2282 for neurofibromatosis type 2-related tumors, and REC-4881 for familial adenomatous polyposis. This matters strategically because Recursion ultimately needs clinical evidence that its platform can generate differentiated medicines, not just interesting datasets.
• Scale the Recursion OS with more compute and richer data modalities. A major initiative has been to increase the amount of biology and chemistry the platform can process. BioHive-1, the NVIDIA-powered supercomputer announced in 2023, is part of that effort. The broader goal is to improve model training, experiment design, and compound prediction by expanding the speed and scale of the underlying system.
• Integrate Cyclica and Valence Discovery into the platform. Recursion’s 2023 acquisitions were capability deals, not classic revenue deals. Cyclica added computational chemistry and polypharmacology tools; Valence brought AI and machine-learning expertise for chemistry. The strategic initiative is to unify these assets with Recursion’s phenomics-heavy platform so target discovery, hit finding, and lead optimization become more tightly connected.
• Use large-pharma partnerships as both validation and financing. Collaborations with companies such as Bayer and Roche/Genentech help Recursion monetize the platform before any wholly owned product reaches market. They also broaden the set of disease areas Recursion can work in without carrying the full R&D burden itself.
• Balance ambition with capital discipline. Recursion is still a development-stage company, so management’s public messaging has consistently paired platform ambition with portfolio prioritization. The strategic challenge is to fund the platform aggressively enough to preserve advantage while avoiding an internal pipeline so broad that it overwhelms capital and operating capacity.

3. What Is the Business Model of Recursion?

As of early 2024, Recursion’s business model was best understood as a hybrid platform-and-pipeline biotech.

What customers actually buy: today, Recursion’s paying customers are primarily pharmaceutical partners that buy access to discovery capabilities, joint research, options, licenses, or other collaboration rights. In the future, if its internal candidates are approved, customers would also buy marketed therapeutics, either from Recursion directly or through partners.

Recurring versus one-time revenue: current revenue is not subscription-like. It is largely driven by collaboration structures that can include upfront payments, research funding, option exercise payments, and milestones. Some revenue can be recognized over multi-year collaboration periods, which creates a partial repeat element, but it is still much less predictable than SaaS or consumables revenue.

Pricing power: in the current model, pricing power depends on how differentiated partners believe the platform is. If Recursion’s data assets, AI, and chemistry capabilities are viewed as hard to replicate, it can negotiate better economics on collaborations. If it eventually commercializes rare-disease or oncology drugs, pricing power would depend more on product efficacy, safety, and competitive alternatives.

Why the business mix matters: collaboration revenue helps fund operations and validates the platform, but the largest long-term economic upside would likely come from wholly or partly owned therapeutics. That creates a classic biotech trade-off: near-term non-dilutive partnership revenue versus long-term product ownership.

What drives margins and cash generation: reported gross margin on collaboration revenue is less informative than in a mature operating company because the real economic engine is R&D investment. Operating margin is negative by design: Recursion spends heavily on research, compute, talent, and clinical development. Cash generation today comes from collaboration cash, equity financing, and occasional strategic capital, not from self-sustaining product sales.

4. What Products and/or Services Does Recursion Sell?

Recursion did not have approved commercial drug products as of mid-2024. Its most important offerings fell into three categories.

• The Recursion OS. This is the strategic core of the company: a technology and biology platform that combines automated wet-lab experimentation, imaging, data infrastructure, machine learning, and computational chemistry. Pharmaceutical partners effectively buy access to the output of this system through collaborations.
• Internal therapeutic candidates. These are the assets with the highest potential long-term value if they succeed clinically. Publicly highlighted clinical-stage programs included REC-994, REC-2282, and REC-4881. These assets are strategically important because they are the clearest test of whether the platform can generate approvable medicines.
• Partnered discovery and development programs. Recursion also offers a collaboration model to larger pharmaceutical companies. In effect, it sells discovery capacity, platform insight, and in some cases downstream rights structures tied to shared programs.
• Newer growth capabilities in chemistry and AI. Following the Cyclica and Valence Discovery acquisitions in 2023, Recursion expanded its capabilities in computational chemistry, molecular design, and AI-driven small-molecule discovery. These are not separate standalone products in the classic software sense; they strengthen the company’s platform offering and internal pipeline productivity.

From a revenue standpoint, collaboration-related offerings mattered most as of 2024. From a strategic standpoint, the internal pipeline and the Recursion OS mattered most.

5. What Are the Key Competitors or Peers of Recursion?

Recursion does not have a single perfect comparable because it combines elements of an AI platform company, a drug-discovery services partner, and a clinical-stage biotech. Its closest competitors are therefore best thought of as peers competing for partnership budgets, talent, assets, and investor capital.

Traditional biotech companies in rare disease and oncology also compete with Recursion for assets, trial sites, and capital, even when they do not share the same platform model.

6. What Is the Marketing Strategy of Recursion?

Recursion’s marketing strategy is unusual because it is pre-commercial. It is not spending meaningfully on consumer marketing or broad physician promotion. Instead, marketing is primarily a scientific reputation and enterprise relationship function.

The company markets itself to four audiences: pharmaceutical partners, scientific collaborators, potential employees, and investors. That means brand-building happens through scientific publications, conference presentations, partnership announcements, investor communications, and thought leadership around TechBio and AI-enabled drug discovery. In effect, Recursion’s version of account-based marketing is business development aimed at senior R&D leaders inside large pharma.

Brand matters, but mostly as a supporting capability rather than the main source of competitive advantage. The company’s core differentiator is intended to be platform output and scientific credibility. Marketing helps convert that into partnerships, talent attraction, and capital market access.

7. What Are the Key Customer Segments of Recursion?

• Large pharmaceutical companies. This is the most important current paying customer segment. Partners use Recursion for discovery collaboration, target identification, and related R&D work. Because Recursion remains pre-commercial, these customers matter more today than end-market prescribers or patients from a revenue standpoint.
• Biotech and research counterparties. These are less central than large pharma but can matter in certain collaborations, licenses, or scientific relationships.
• Future specialty-care prescribers, patients, and payers. If Recursion commercializes its own assets, the economically relevant customer base would shift toward rare-disease and oncology stakeholders. That future customer set would likely be narrower but high value, especially in specialist indications.

At present, Recursion’s revenue base appears concentrated by customer because a small number of collaboration agreements drive most reported revenue. That concentration is common for platform biotechs but makes partner quality and alliance management especially important.

8. What Is the Sales Model of Recursion?

Recursion’s current sales model is direct enterprise selling into the pharmaceutical industry, supported by scientific diligence and executive-level relationship building. It is not a distributor, retail, or channel-driven model.

For collaboration deals, the practical sales motion likely involves business development leaders, senior scientists, and management working directly with pharmaceutical-company R&D and strategy teams. The sales cycle is therefore long, technical, and highly customized. Growth comes from a small number of large, complex relationships rather than thousands of smaller transactions.

This structure has important implications. It can preserve pricing and strategic control because there are no middlemen, but it also means growth is uneven and dependent on deal timing. It creates high customer intimacy with partners and makes alliance governance a critical capability. As of 2024, Recursion did not need a broad commercial field sales force because it had no approved product to promote.

9. In What Geographies Does Recursion Operate?

Recursion’s operational footprint is concentrated but international.

• United States: Salt Lake City is the company’s headquarters and a major center for its platform, research, and clinical operations.
• Canada: The 2023 acquisitions of Cyclica and Valence Discovery added meaningful chemistry and AI capabilities in Toronto and Montreal.
• Europe and broader global markets: Recursion’s partnerships connect it to large pharmaceutical companies with global footprints, including companies based in Europe and the U.S. Clinical development can also involve international sites depending on the program.

So while the company is not globally dispersed in the way a large pharmaceutical manufacturer is, it is also not purely domestic. Its operations are North America-centered, while its customer and development relevance is broader and increasingly international.

10. Who Are the Owners of Recursion?

Recursion is a publicly traded company. As reflected in recent proxy-era disclosures, ownership is dispersed across founders, venture investors, and public-market institutions rather than concentrated in a single controlling shareholder. Among the better-known holders historically and in recent disclosures have been entities affiliated with Lux Ventures and large institutional investors such as Baillie Gifford. NVIDIA also became an equity holder through its 2023 strategic investment. Co-founder and CEO Chris Gibson and other insiders held meaningful but non-controlling stakes. No majority owner was publicly disclosed.

11. How Is Recursion Organized?

Legally, Recursion Pharmaceuticals, Inc. is the listed parent company. From a reporting standpoint, it has disclosed one operating and reportable segment, which is common for a clinical-stage biotech.

Operationally, the company appears to be organized around an integrated model rather than separate siloed divisions. In practice, that likely means four major layers:

• Platform and technology: data generation, engineering, AI, compute, and software.
• Discovery and preclinical research: biology, chemistry, translational science, and candidate selection.
• Clinical development: regulatory, medical, clinical operations, and portfolio advancement.
• Corporate and alliance functions: business development, finance, legal, people, and partner management.

The practical challenge in this structure is coordination. Recursion has to operate like a technology company, a discovery engine, and a drug developer at the same time.

12. How Does Recursion Operate?

Recursion’s day-to-day operating model is built around an iterative loop between experimental biology and computation.

1. Generate biological data at scale. The company perturbs cells and other biological systems, captures phenotypic changes through imaging and related methods, and creates large proprietary datasets.
2. Convert experiments into machine-readable signals. Computer vision and other machine-learning methods are used to detect patterns in those experiments and map relationships among genes, compounds, and phenotypes.
3. Use those insights to identify targets and compounds. This is where platform science connects to drug discovery economics. The aim is to improve hit identification, prioritization, and lead optimization.
4. Advance selected programs through preclinical and clinical development. Internal assets move into more traditional biotech workflows such as toxicology, regulatory preparation, clinical operations, and trial execution.
5. Monetize both internally and externally. Some discoveries feed Recursion’s own pipeline; others support partnered programs.
6. Feed results back into the platform. Every successful or failed experiment is intended to improve future model performance and portfolio decisions.

The main operational complexities are scientific translation risk, compute intensity, cross-functional coordination, and portfolio prioritization. Recursion must continuously decide whether the next dollar is best spent on more data generation, more AI infrastructure, or more direct clinical progress.

13. What Are the Growth Opportunities for Recursion?

• Clinical validation of the platform. The most important growth opportunity is simple: if one or more internal programs show compelling clinical data, the company’s economics and credibility could change substantially.
• More and better pharmaceutical collaborations. Strong platform performance can support additional partnerships, richer deal economics, and possibly broader scope within existing alliances.
• Expansion of multimodal data and compute. If Recursion’s larger-scale AI and compute investments improve discovery productivity, the platform itself becomes more valuable with every cycle.
• Broader use of chemistry capabilities. The integration of Cyclica and Valence creates an opportunity to strengthen small-molecule design and move more seamlessly from biological signal to optimized compound.
• Selective ownership of high-value assets. Recursion could create more shareholder value by keeping greater economics in programs where it has high conviction, especially in specialty indications with feasible commercial footprints.
• Capability-led M&A or in-licensing. The company can continue to expand the platform by acquiring tools, teams, or programs that fit its operating model.

The main constraints are equally clear: clinical failure risk, the difficulty of proving that AI materially changes drug-development outcomes, partner concentration, integration complexity, and the need to manage cash burn while investing in platform scale.

14. What Is the History of Recursion?

Recursion was founded in 2013 in Salt Lake City by Chris Gibson and Dean Li. From the beginning, the company positioned itself around the idea that large-scale experimental biology and computation could reveal drug opportunities that conventional approaches might miss.

Over time, Recursion built a reputation around image-based phenomics, automation, and a growing data platform. In 2020, it announced a major collaboration with Bayer, giving outside validation to the platform approach. In 2021, Recursion went public on Nasdaq and also announced a collaboration with Roche and Genentech, another important signal that large pharmaceutical companies were willing to buy into the model.

In 2023, the company made two notable acquisitions: Cyclica and Valence Discovery. Both deals were intended to deepen chemistry and AI capabilities. That same year, NVIDIA made a strategic investment in Recursion, and the company announced BioHive-1, a major supercomputing initiative. By early 2024, Recursion had become one of the better-known public companies trying to define the TechBio category.

15. How Is Recursion Using AI?

AI is not a side project at Recursion; it is embedded in the company’s operating model.

• Live use case: computer vision on biological experiments. Recursion uses machine learning to interpret high-content cellular images and other experimental outputs, turning visual phenotypes into searchable quantitative data.
• Live use case: relationship mapping across biology and chemistry. The company uses machine-learning methods to model connections among genes, compounds, and phenotypic outcomes in order to identify targets and prioritize programs.
• Live use case: computational chemistry and molecular design. The Cyclica and Valence Discovery acquisitions expanded Recursion’s ability to use AI in small-molecule discovery and optimization.
• Live infrastructure: high-performance computing. BioHive-1, built with NVIDIA technology and announced in 2023, is intended to support large-scale model training and inference.
• Ongoing initiative: multimodal models. Public company materials indicate that Recursion is working to integrate more data types across biology and chemistry. The direction is clear, even if the final performance gains remain an ongoing rather than completed outcome.

The key point is that Recursion is using AI in production discovery workflows today, while still trying to push toward larger and more capable models over time.

16. What Is the Technology Strategy of Recursion?

Recursion’s technology strategy is to treat the discovery platform itself as a compounding asset. That means investing not only in algorithms, but also in the full system required to make those algorithms useful: lab automation, imaging hardware, software pipelines, cloud and high-performance compute, data infrastructure, and scientific tooling.

Technology serves two roles at Recursion. First, it is an internal enabler that helps generate and interpret experiments faster and at larger scale. Second, it is part of the company’s customer offering because pharmaceutical partners are effectively buying the output of this technology stack when they enter collaborations.

The company’s strategy appears to favor vertical integration in the most strategically important parts of the stack. Rather than being just an AI layer sitting on external data, Recursion has built technology around generating proprietary data, processing it, and linking it to therapeutic decisions. That makes the technology strategy central to competitiveness, not just a support function.

17. What Is the R&D Strategy of Recursion?

Recursion’s R&D strategy is to industrialize early-stage discovery while retaining enough therapeutic focus to produce clinical proof. In practice, that means using the platform to generate many hypotheses, then applying portfolio discipline to select a smaller number of programs for expensive downstream development.

Several aspects of the R&D strategy stand out:

• Platform-led discovery: discovery is supposed to begin with large-scale data and model-driven insight rather than solely literature-driven target selection.
• Parallelized experimentation: automation allows many experiments to run at once, which can improve cycle time and search breadth.
• Blend of internal and partnered R&D: Recursion uses collaborations to spread risk and access more biology while keeping some programs for internal value creation.
• Focus on tractable indications: the company’s internal priorities suggest a preference for areas where biology may be sufficiently defined to generate meaningful proof points.

R&D is therefore not just a cost center at Recursion; it is the mechanism through which the platform proves its value. The company’s challenge is to show that scale in experimentation and computation actually improves the odds of producing clinically useful drugs.

18. What Is the Finance Strategy of Recursion?

Recursion’s finance strategy is shaped by the realities of a pre-commercial biotech. The company is not optimizing for near-term earnings; it is optimizing for runway, flexibility, and selective reinvestment.

Several features define that approach:

• Use collaboration economics to offset burn. Partnerships provide non-dilutive capital and can help fund platform investment before product revenue exists.
• Prioritize R&D and platform spending. Cash is directed first toward the Recursion OS, clinical programs, and capability-building initiatives rather than dividends or buybacks.
• Use strategic capital when available. NVIDIA’s 2023 equity investment is a good example of financing that also reinforces the company’s technology agenda.
• Manage portfolio breadth. Capital allocation is especially important because every additional internal program raises future trial and development costs.
• Keep optionality for future deals. Selective acquisitions, licensing, or collaboration structures remain part of the toolkit.

Working-capital dynamics are different from those of an industrial company. Inventory and receivables are not the main story; the main financial variables are payroll, compute, laboratory spend, external research, and clinical-development cash usage.

19. What Major Acquisitions Has Recursion Made?

Recursion’s acquisition strategy has been capability-led rather than scale-led. It has used M&A to strengthen the platform, especially in chemistry and AI.

These deals suggest Recursion views M&A as a way to accelerate platform completeness. The logic is less about buying revenue and more about closing capability gaps that could limit discovery productivity.

20. How Companies Like Recursion Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of over 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Recursion engage Umbrex when they need talent with the training these firms provide, but do not need a full consulting team and the related overhead. Umbrex has independent consultants across strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI. For a company like Recursion, the best uses are typically high-value, decision-oriented projects that sit at the intersection of platform scale, portfolio choices, and operating discipline.

• Portfolio prioritization: build a decision framework to compare internal programs, partnered programs, and platform investments on risk-adjusted value and capital needs.
• Platform operating model design: clarify decision rights and handoffs among AI, biology, chemistry, translational science, and clinical teams.
• Acquisition integration: help integrate Cyclica- and Valence-derived capabilities into one coherent discovery workflow, governance model, and KPI set.
• Alliance strategy and value capture: improve governance, milestone planning, and joint-working models for partnerships with large pharmaceutical companies.
• Compute and data economics: assess cloud versus high-performance compute trade-offs, vendor strategy, utilization, and ROI from major infrastructure investments such as BioHive-type capacity.
• Clinical development acceleration: redesign trial operations for rare-disease programs, including site strategy, enrollment planning, and cross-functional issue resolution.
• Commercial readiness planning: prepare scenarios for a first specialty launch, including market sizing, access strategy, patient journey mapping, and go-to-market choices for rare-disease or oncology assets.
• Finance and runway planning: create capital-allocation scenarios tied to pipeline events, partnership options, and financing alternatives.
• Procurement and external-spend optimization: improve management of contract research organizations, contract development and manufacturing organizations, software vendors, and specialized technology suppliers.
• AI governance and data strategy: design practical governance around model usage, data quality, experiment prioritization, and executive reporting so AI investments translate into operating decisions.